Develops regenerative medicines for gastrointestinal and bone disorders, focusing on Wnt pathway modulation.
Surrozen, Inc. is a pioneering biotechnology company dedicated to the discovery and advancement of drug candidates that selectively modulate the Wnt pathway to facilitate tissue repair and regeneration. The company's innovative approach involves developing tissue-specific antibodies tailored for applications across a spectrum of diseases affecting various organs. These include conditions affecting the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Through its research and development efforts, Surrozen aims to harness the therapeutic potential of the Wnt pathway in addressing critical medical needs across diverse therapeutic areas.
At the forefront of Surrozen's pipeline is SZN-043, a promising tissue-specific R-spondin mimetic designed specifically for the treatment of severe liver diseases. Additionally, the company is advancing SZN-1326, a bi-specific full-length human antibody. This innovative antibody modulates Wnt signaling directly within target tissues by selectively binding to specific Frizzled and LRP receptors expressed in intestinal crypts. These advancements underscore Surrozen's commitment to leveraging its proprietary technology to develop novel therapeutic solutions that hold promise for patients suffering from a range of debilitating conditions.
Founded in 2015 and headquartered in South San Francisco, California, Surrozen, Inc. has established itself as a leader in the field of Wnt pathway modulation. With a robust pipeline of potential therapies and a dedication to scientific excellence, Surrozen continues to push the boundaries of biotechnology to address unmet medical needs and enhance outcomes for patients worldwide.